Zenas BioPharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Zenas BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $42.13. The average 1-year stock price forecast is 64.89% higher than the current stock price, while the lowest is $22 (-13.89%) and the highest is $55 (+115.26%).

Price Target: $42.13 (+64.89%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$22	$42.13	$44.5	$55
Change	-13.89%	+64.89%	+74.17%	+115.26%

Analyst Ratings

The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	7	7
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Buy Reiterates $44	Buy	Reiterates	$44	+72.21%	Jun 8, 2026
Yatin Suneja Guggenheim	Guggenheim	Buy Maintains $55	Buy	Maintains	$55	+115.26%	Jun 5, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Hold Maintains $21 → $22	Hold	Maintains	$21 → $22	-13.89%	May 14, 2026
David Nierengarten Wedbush	Wedbush	Buy Maintains $45	Buy	Maintains	$45	+76.13%	May 14, 2026
Yigal Nochomovitz Citi	Citi	Buy Reiterates $41	Buy	Reiterates	$41	+60.47%	May 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

36.26M

from 10.00M

262.60%

from 10.00M

Revenue Next Year

63.25M

from 36.26M

74.43%

from 36.26M

EPS This Year

-4.33

from -4.83

EPS Next Year

-2.27

from -4.33

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	50.00M	5.00M	10.00M	36.26M
Revenue Growth	-	-	-90.00%	100.00%	262.60%
Gross Profit	-61.69M	-10.03M	-134.14M	-158.06M	32.63M
Gross Margin	-	-20.07%	-2,682.78%	-1,580.63%	90.00%
Operating Income	-75.20M	-27.15M	-163.89M	-211.39M	-274.33M
Net Income	-119.28M	-37.12M	-156.99M	-377.74M	-284.95M
EPS	-	-	-	-4.83	-4.33
Free Cash Flow	-	-17.64M	-60.01M	-143.11M	-271.19M
No. Analysts	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	75.0M
Avg	36.3M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	650.0%
Avg	262.6%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-4.33
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-